| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 2.17 | 20.6% | 90.3% |
| Total Income | 2.17 | 20.6% | 90.3% |
| Expenditure | 9.87 | 10.3% | 43.9% |
| PBT | — | ||
| Net Profit | -7.14 | 16.6% | 53.0% |
| OPM | — | ||
| NPM | — | ||
| EPS | -3.72 | 16.6% | 830.0% |
Bolt Biotherapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 7:27 am
Summary
Bolt Biotherapeutics reported financial results for the third quarter ended September 30, 2025. The company's cash balance was $38.8 million as of September 30, 2025, expected to fund milestones into 2027. Collaboration revenue increased to $2.2 million from $1.1 million in the same quarter of the previous year. The company's loss from operations decreased to $7.7 million compared to $16.4 million for the same quarter in 2024.
Key Highlights
- 1
Bolt Biotherapeutics reported a cash balance of $38.8 million as of September 30, 2025, which is anticipated to fund key milestones into 2027.
- 2
Collaboration revenue was $2.2 million for the quarter ended September 30, 2025, compared to $1.1 million for the same quarter in 2024.
- 3
Research and Development expenses were $6.5 million for the quarter ended September 30, 2025, compared to $13.8 million for the same quarter in 2024.
- 4
General and Administrative expenses were $3.3 million for the quarter ended September 30, 2025, compared to $3.8 million for the same quarter in 2024.
- 5
Loss from operations was $7.7 million for the quarter ended September 30, 2025, compared to $16.4 million for the same quarter in 2024.
Management Comments
Willie Quinn
“In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline. We are actively enrolling patients with gastric and gastroesophageal cancer in the Phase 1 dose-escalation study. We now look forward to presenting initial data in the third quarter of 2026. With our cash runway now expected to extend into 2027, we are in a financial position to create long-term value for our shareholders and fulfill our mission of bringing new treatment options to patients with cancer.”
Informational and educational content only. Not investment advice.